乳腺癌激素受体、CerbB-2、P53、nm23基因的表达及与临床病理特征的关系

目的:探讨雌激素受体(ER)、孕激素受体(PR)及C-erbB-2、P53、nm23基因在乳腺癌组织中的表达及其与临床病理特征之间的关系。方法:用免疫组织化学S-P法检测113例乳腺癌组织中ER、PR及C-erbB-2、P53、nm23的表达。并结合乳腺癌临床病理特征进行分析。结果:113例乳腺癌组织中ER、PR及C-erbB-2、P53、nm23阳性表达率分别为49.6%、39.8%、59.3%、40.7%和71.7%,与临床分期、肿瘤大小、病理类型、年龄无关(P>0.05);C-erbB-2、P53阳性表达率与腋淋巴结转移呈正相关(P<0.05)。nm23阳性表达率与腋淋巴结转移呈负相关(P<0.05)。ER和(或)PR、nm23阳性组乳腺癌复发率低于阴性组(P<0.05)。C-erbB-2、p53阳性组乳腺癌复发率高于阴性组(P<0.05)。C-erbB-2的表达在ER、PR阴性组高于阳性组(P<0.05)。结论:联合检测ER、PR与C-erbB-2、P53、nm23表达对判断乳腺癌的预后、指导临床治疗具有十分重要的意义。     

乳腺癌中ER、PR和C-erbB-2的表达及与淋巴结转移的关系

目的 探讨乳腺癌中雌激素受体(ER)、孕激素受体(PR)、C-erbB-2癌基因表达及其与腋窝淋巴结转移的关系.方法 采用常规免疫组化SP法检测182例乳腺癌组织中ER、PR、C-erbB-2的表达.结果 ①ER、PR、C-erbB-2的阳性率分别为42.9%(78/182)、53.8%(98/182)、50.5%(92/182).②C-erbB-2在ER、PR均阳性组的表达低于二者均阴性组的表达 (P＜0.05);淋巴结转移组中C-erbB-2的表达率高于淋巴结未转移组(P＜0.05).③ER的表达与PR的表达呈显著正相关,ER、PR的表达与患者的年龄、肿瘤大小、病理类型无关.结论 ER、PR和C-erbB-2与乳腺癌的发生发展有关,ER、PR 及C-erbB-2的测定是判断乳腺癌预后的重要指标,而且可以为临床制定乳腺癌的综合治疗方案提供重要依据.     

乳腺癌组织中雌、孕激素受体及C-erbB-2基因的表达与预后关系的探讨

目的探讨雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)和C-erbB-2基因在乳腺癌组织中的表达及其临床意义。方法采用免疫组织化学SP法检测254例乳腺癌组织中ER、PR及C-erbB-2的表达。结果ER、PR及C-erbB-2的阳性表达率分别为54.05%、62.59%和54.72%;ER、PR的阳性表达与腋淋巴结转移呈负相关(P<0.05);C-erbB-2的阳性表达与腋淋巴结转移呈正相关(P<0.05),与肿瘤大小、临床分期、复发转移及生存相关,阴性表达组5年生存明显优于阳性表达组;三者的表达状况与年龄、绝经与否及病理类型均无关;ER与PR的表达呈显著正相关,ER、PR和C-erbB-2之间的表达呈负相关(P<0.05)。结论联合检测乳腺癌组织中ER、PR和C-erbB-2的表达对乳腺癌患者治疗方案的制定和判断预后有重要意义。     

乳腺癌nm23基因和雌孕激素受体的表达与组织学分级及预后关系的研究

目的 研究乳腺癌nm23基因、雌激素受体(Estrogen-receptor,ER)、孕激素受体(Progestin-receptor,PR)表达与组织学分级及预后关系. 方法 应用S-P免疫组织化学染色方法,研究转移性抑制基因nm23及雌孕激素受体在160例乳腺癌组织中的表达变化. 结果 nm23基因表达与乳腺癌病理组织学分级之间无显著相关性(P＞0.05),而与淋巴结转移及预后有显著相关性(P＜0.05).乳腺癌有淋巴结转移组nm23基因阳性表达率明显低于无淋巴结转移组,而死亡率明显高于无淋巴结转移组.ER、PR阳性表达与乳腺癌病理组织学分级有显著相关性,即组织学分级愈低,ER、PR阳性表达率愈高.ER、PR阳性表达与淋巴结转移有显著相关性,(P＜0.01),即有淋巴结转移者ER、PR阳性表达率低,无淋巴结转移者ER、PR 阳性表达率高.ER、PR表达阳性组5年存活率明显高于ER、PR表达阴性组(P＜0.05). 结论 检测乳腺癌组织中的nm23基因及雌孕激素受体对临床正确判断乳腺癌病人的预后有一定的参考价值.     

乳腺癌组织雌激素和孕激素受体及c-erbB-2的表达

目的 探讨乳腺癌组织雌激素受体(ER)、孕激素受体(PR)和c-erbB-2的表达状况及其与预后因素的相关性.方法 回顾1 008例乳腺癌患者的临床资料.分析乳腺癌组织ER、PR、c-erbB-2表达与患者月经状态、腋淋巴结转移情况及肿瘤TNM分期等预后因素之间的关系.结果 1 008例乳腺癌患者平均年龄(53.53±12.60)岁;浸润性导管癌占80.5%.绝经后ER阳性者显著多于绝经前,且临床分期较早(P＜0.05);绝经前后ER/PR双阳性与双阴性者无显著性差异(P＞0.05);PR阴性、ER/PR双阴性与腋淋巴结转移与否显著相关(P＜0.05);ER阴性或ER/PR双阴性者的c-erbB-2阳性表达率显著高于ER阳性或ER/PR双阳性者(P＜0.05).结论 ER、PR、c-erbB-2参与了乳腺癌生物学行为的调控.ER、PR表达状态与患者月经状态、腋淋巴结转移、肿瘤临床分期及c-erbB-2表达状况有关.     

乳腺癌c-erbB-2原癌基因与ER、PR的关系和临床意义

目的 探讨乳腺癌组织中c-erbB-2原癌基因和ER、PR表达关系及其临床意义.方法 采用免疫组织化学方法对我院95例乳腺癌组织进行c-erbB-2和ER、PR测定,分析它们之间的表达关系及其临床意义.结果 c-erbB-2阳性表达者占69.47%.c-erbB-2阳性率在ER阳性组为48.39%,在ER阴性组为79.69%(P＜0.005);c-erbB-2阳性率在PR阳性组为48.15%,在PR阴性组为77.94%(P＜0.01).,随诊2年以上,激素受体阳性复发率约为4%,阴性者约为13%,c-erbB-2阳性复发率为14.0%,阴性者为2.5%(P＜0.05).结论 c-erbB-2阳性表达与ER、PR阳性表达呈负相关,c-erbB-2是判断乳腺癌预后的有效指标,联合检测C-erbB-2、ER、PR可指导临床综合治疗.     

ER、PR、C-erbB-2、P53及 Ki-67在乳腺癌组织中表达的相关性研究

目的 探讨乳腺癌组织中 ER、PR、C-erbB-2、P53及Ki-67 的表达情况及它们的相关性.方法 采用免疫组化检测138 例乳腺癌组织的ER、PR、C-erbB-2、P53及 Ki-67 的表达,并对它们与临床病理特征的关系以及它们之间的表达相关性进行分析.结果 ER、PR、C-erbB-2、P53和Ki-67 阳性表达率分别为62.31%、59.42%、50.72%、43.47%、60.14%.ER、PR 阳性表达与肿瘤大小,淋巴结转移无相关性,与组织学分级和病理分期相关.C-erbB-2 、Ki-67与有无淋巴结转移、肿瘤病理分期相关( P 均< 0.05),Ki-67还与肿瘤组织分级相关( P< 0.05).而P53与乳腺癌组织病理特征无明显相关性.ER 与PR 表达呈正相关,与P53阳性表达无明显相关性,与C-erbB-2、Ki-67 表达呈负相关(P均<0.01).Ki-67、P53、C-erbB-2表达呈正相关(P<0.05).结论 检测乳腺癌组织的ER、PR、C-erbB-2、P53及 Ki-67 的表达情况有助于了解乳腺癌的生物学行为,为乳腺癌的个性化治疗提供依据,对预后评估有重要意义.     

乳腺癌中的ER,PR,P53,C-erbB-2和PCNA的表达及临床意义

目的:探讨乳腺癌组织中雌激素受体(ER),孕激素受体(PR),p53,C-erbB-2和增殖细胞核抗原(PCNA)在乳腺癌中的表达和与临床病理的关系.方法:应用免疫组化方法检测经病理证实的92例乳腺癌组织ER,PR,p53,C-erbB-2和PCNA的表达.结果:92例患者ER,PR,P53,C-erbB-2和Pc-NA表达的阳性率分别为60.9%,58.8%,29.3%,71.7%和59.8%.ER的表达在不同肿瘤大小、腋窝淋巴结有无转移组别中差异有统计学意义(P<0.05);PR的表达与年龄、肿瘤大小、分期及淋巴结转移情况均无统计学意义(P>0.05);而C-erbB-2和PCNA在淋巴结有无转移之间表达差异具有统计学意义(P<0.05).结论:联合检测乳腺癌组织中ER,PR,P53,C-erbB-2和PCNA的表达对于判断乳腺癌预后和指导治疗具有临床参考价值.     

C-erbB-2、P53、ER和PR在乳腺癌中的表达及意义

目的:探讨C-erbB-2、P 53、ER和PR蛋白在乳腺癌中的表达及其临床意义。方法:采用免疫组化SP方法,检测54例乳腺癌组织及其癌旁正常乳腺组织中C-erbB-2、P 53、ER和PR蛋白的表达情况。结果:在54例乳腺癌中C-erbB-2、P 53、ER和PR蛋白阳性表达率分别为87.0%(47/54)、83.3%(45/54)、66.7%(36/54)和61.1%(33/54);C-erbB-2和P 53阳性表达率与临床分期、有无淋巴结转移有关(P<0.05);C-erbB-2、P 53、ER和PR阳性表达率与肿瘤大小无关(P>0.05)。C-erbB-2和P 53共同阳性表达与淋巴结转移有关(P<0.01)。结论:联合检测乳腺癌C-erbB-2、P 53、ER和PR基因蛋白对判断预后和指导内分泌治疗有实用价值。     

联合检测C-erbB-2、P53、ER、PR在乳腺癌组织中的表达及意义

目的：探讨C-erbB-2、P53及雌激素受体和孕激素受体在乳腺癌中的表达和临床病理关系.方法：148例乳腺癌石蜡切片标本SP法免疫组化检测.结果：148例乳腺癌中C-erbB-2、P53、ER、PR的阳性表达率分别为82.6％、79.3％、64.3％、59.7％,C-erbB-2、P53的表达与乳腺癌转移与预后呈正相关,ER、PR的表达与乳腺癌的转移和预后呈负相关.结论：C-erbB-2、P53的阳性表达是乳腺癌患者预后差的指标,ER、PR的表达提示乳腺癌患者预后好,联合检测C-erbB-2、P53、ER、PR有助于乳腺癌患者的治疗和预后判断.     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…